Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos
Autor(a) principal: | |
---|---|
Data de Publicação: | 2008 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações do UFSM |
Texto Completo: | http://repositorio.ufsm.br/handle/1/8938 |
Resumo: | The α₂-adrenergic receptor agonists are widely used in equine practice, especially in antalgic therapy, because they promote profound sedation and moderate visceral analgesia. The opioids are used in horses with some restriction due to the excitatory effects in this specie. The objective of this study was to evaluate the sedative effect, hemodynamic, pulmonary and digestory changes due to the neuroleptoanalgesic association of buprenorphine and different doses of xylazine. Six adults horses of both gender, weighting an average of 400 Kg. The animals were control of themselves, being divided into four groups, control group (CG) saline NaCl 0,9% solution administrated IV, and three other groups with buprenorphine 10 μg/kg associated to three different doses of xylazine, 0,25 mg/kg (BX25), 0,50 mg/kg (BX50) and 0,75 mg/kg (BX75) IV. Sedative effects, gastrointestinal motility, FC, f, SAP, MAP, DAP, blood gas tension analysis and core temperature were evaluated 30 min before, immediately before the administration of any treatment for basal values and after 5, 15 and every 15 min until 120 min post-treatment. Gastrointestinal motility was evaluated by the same period and for 12 hours, every 2 hours. Blood samples were collected at 0, 30 and 60 min. Parametric variables were analyzed with ANOVA, followed by Dunnett test for intra group and Tukey test between groups. For the non-parametric variable (intestinal motility) Wilcoxon test was used. Differences was considered significant when P<0.05. Intense sedative effect was observed in the three groups with the neuroleptoanalgesic association lasting 45 min in BX75 with profound ataxia. Intestinal motility decreased with 5 minutes after administration and remained decreased for 8 hours. Hemodynamic parameters started to increased after 30 min and no changes were observed in respiratory frequency and blood gas samples analysis, only HCO3- showed increase. Synergistic effect was observed, maintaining hemodynamic stability, with minimal pulmonary effects. The hypomotility observed must be considered when the association is used in horses with gastrointestinal disorders. |
id |
UFSM_135d444ab97ae47e0d4b69f4d51b6c6b |
---|---|
oai_identifier_str |
oai:repositorio.ufsm.br:1/8938 |
network_acronym_str |
UFSM |
network_name_str |
Biblioteca Digital de Teses e Dissertações do UFSM |
repository_id_str |
|
spelling |
2009-03-092009-03-092008-08-08CRUZ, Fernando Silvério Ferreira da. Physiological changes and sedative effects of the association between buprenorphine and xylazine in horses. 2008. 78 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2008.http://repositorio.ufsm.br/handle/1/8938The α₂-adrenergic receptor agonists are widely used in equine practice, especially in antalgic therapy, because they promote profound sedation and moderate visceral analgesia. The opioids are used in horses with some restriction due to the excitatory effects in this specie. The objective of this study was to evaluate the sedative effect, hemodynamic, pulmonary and digestory changes due to the neuroleptoanalgesic association of buprenorphine and different doses of xylazine. Six adults horses of both gender, weighting an average of 400 Kg. The animals were control of themselves, being divided into four groups, control group (CG) saline NaCl 0,9% solution administrated IV, and three other groups with buprenorphine 10 μg/kg associated to three different doses of xylazine, 0,25 mg/kg (BX25), 0,50 mg/kg (BX50) and 0,75 mg/kg (BX75) IV. Sedative effects, gastrointestinal motility, FC, f, SAP, MAP, DAP, blood gas tension analysis and core temperature were evaluated 30 min before, immediately before the administration of any treatment for basal values and after 5, 15 and every 15 min until 120 min post-treatment. Gastrointestinal motility was evaluated by the same period and for 12 hours, every 2 hours. Blood samples were collected at 0, 30 and 60 min. Parametric variables were analyzed with ANOVA, followed by Dunnett test for intra group and Tukey test between groups. For the non-parametric variable (intestinal motility) Wilcoxon test was used. Differences was considered significant when P<0.05. Intense sedative effect was observed in the three groups with the neuroleptoanalgesic association lasting 45 min in BX75 with profound ataxia. Intestinal motility decreased with 5 minutes after administration and remained decreased for 8 hours. Hemodynamic parameters started to increased after 30 min and no changes were observed in respiratory frequency and blood gas samples analysis, only HCO3- showed increase. Synergistic effect was observed, maintaining hemodynamic stability, with minimal pulmonary effects. The hypomotility observed must be considered when the association is used in horses with gastrointestinal disorders.Os agonistas α₂-adrenérgicos são amplamente empregados na clínica equina, destacando-se na terapia antálgica pela intensa sedação e por produzirem moderada analgesia visceral. Os opióides, apesar de serem utilizados na terapia antálgica de equinos, parecem ainda ter seu uso relativamente restrito, principalmente pela excitação observada quando da utilização destes. O estudo teve como objetivo investigar o efeito sedativo e as alterações hemodinâmicas, pulmonares e digestória decorrentes da utilização da associação neuroleptoanalgésica entre a buprenorfina e diferentes doses de xilazina. Utilizou-se 6 equinos de ambos os sexos, com média de peso de 400kg. Os animais foram divididos em quatro grupos autocontrole, sendo grupo controle, administração de solução fisiológica 0,9% IV, e outros três grupos, com a associação de buprenorfina 10 μg/kg associada a diferentes doses de xilazina, 0,25 mg/kg (BX25), 0,5 mg/kg (BX50) e 0,75 mg/kg (BX75) IV. Avaliouse a atividade sedativa, motilidade intestinal, FC, f, PAS, PAM, PAD, parâmetros hemogasométricos e temperatura corpórea aos 30 min antes, imediatamente antes da administração de qualquer substância para determinação dos valores basais e aos 5min, 15 min, e a cada 15 min até 120 min após o tratamento. A motilidade intestinal foi avaliada pelo mesmo período nos mesmos tempos e a cada duas horas até 12 horas após a administração. Os parâmetros hemogasométricos foram avaliados aos 0, 30 e 60 min. Para as variáveis paramétricas utilizou-se análise de variância para amostras pareadas, com posterior teste de Dunnett. Para comparações entre os grupos, realizou-se análise de variância, seguido de teste de Tukey. Para a variável não-paramétrica, motilidade intestinal, utilizou-se teste de Wilcoxon para amostras pareadas. As diferenças foram consideradas significantes quando P<0,05. Foi observado efeito sedativo significante nos três grupos com a associação neuroleptoanalgésica, perdurando por até 45 min no BX75 com severa ataxia. Observou-se hipomotilidade 5 minutos após a administração perdurando por 480 min. Os parâmetros hemodinâmicos elevaram-se após os 45 min, não sendo observadas alterações na frequência respiratória e nos parâmetros hemogasométricos, ocorrendo aumento somente no HCO3-. Conclui-se que houve efeito sinérgico entre os dois fármacos, mantendo estabilidade hemodinâmica, com mínimas alterações pulmonares. A hipomotilidade promovida pela associação deve ser considerada quando usada em equinos com distúrbios gastrintestinais.application/pdfporUniversidade Federal de Santa MariaPrograma de Pós-Graduação em FarmacologiaUFSMBRFarmacologiaXilazinaBuprenorfinaEquinosSedaçãoAnalgesiaXylazineBuprenorphineHorsesSedationAnalgesiaCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIAAlterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinosPhysiological changes and sedative effects of the association between buprenorphine and xylazine in horsesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisCarregaro, Adriano Bonfimhttp://lattes.cnpq.br/5041153897534751Corte, Flavio Desessards de Lahttp://lattes.cnpq.br/4040388452531898Queiroz Neto, Antonio dehttp://lattes.cnpq.br/6695662273447490http://lattes.cnpq.br/4262392857518163Cruz, Fernando Silvério Ferreira da201000000000400500300500300a0421801-2f7d-45b2-a7fb-c0b089433af7e3ab06bd-3d28-4b33-a997-93ba02edaec5ab8aec2d-f3fe-45a4-8bc3-07256644578f19e8f84b-7ad7-4606-973b-baf5993524dbinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações do UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSMORIGINALDIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdfDissertação de Mestradoapplication/pdf1155142http://repositorio.ufsm.br/bitstream/1/8938/1/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf3e604c1ba91c9deddf24078cec533efaMD51TEXTFERNANDOSILVERIOFERREIRADACRUZ.pdf.txtFERNANDOSILVERIOFERREIRADACRUZ.pdf.txtExtracted texttext/plain126181http://repositorio.ufsm.br/bitstream/1/8938/2/FERNANDOSILVERIOFERREIRADACRUZ.pdf.txtc079ba0edf55cd3487bf2dd8cb441a5bMD52DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.txtDIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.txtExtracted texttext/plain126181http://repositorio.ufsm.br/bitstream/1/8938/4/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.txtc079ba0edf55cd3487bf2dd8cb441a5bMD54THUMBNAILFERNANDOSILVERIOFERREIRADACRUZ.pdf.jpgFERNANDOSILVERIOFERREIRADACRUZ.pdf.jpgIM Thumbnailimage/jpeg4958http://repositorio.ufsm.br/bitstream/1/8938/3/FERNANDOSILVERIOFERREIRADACRUZ.pdf.jpgcb148c0b9b3c781472aa1c40a1bb1c68MD53DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.jpgDIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.jpgIM Thumbnailimage/jpeg4958http://repositorio.ufsm.br/bitstream/1/8938/5/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.jpgcb148c0b9b3c781472aa1c40a1bb1c68MD551/89382023-04-20 10:16:40.361oai:repositorio.ufsm.br:1/8938Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2023-04-20T13:16:40Biblioteca Digital de Teses e Dissertações do UFSM - Universidade Federal de Santa Maria (UFSM)false |
dc.title.por.fl_str_mv |
Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos |
dc.title.alternative.eng.fl_str_mv |
Physiological changes and sedative effects of the association between buprenorphine and xylazine in horses |
title |
Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos |
spellingShingle |
Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos Cruz, Fernando Silvério Ferreira da Xilazina Buprenorfina Equinos Sedação Analgesia Xylazine Buprenorphine Horses Sedation Analgesia CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
title_short |
Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos |
title_full |
Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos |
title_fullStr |
Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos |
title_full_unstemmed |
Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos |
title_sort |
Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos |
author |
Cruz, Fernando Silvério Ferreira da |
author_facet |
Cruz, Fernando Silvério Ferreira da |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Carregaro, Adriano Bonfim |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/5041153897534751 |
dc.contributor.referee1.fl_str_mv |
Corte, Flavio Desessards de La |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/4040388452531898 |
dc.contributor.referee2.fl_str_mv |
Queiroz Neto, Antonio de |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/6695662273447490 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/4262392857518163 |
dc.contributor.author.fl_str_mv |
Cruz, Fernando Silvério Ferreira da |
contributor_str_mv |
Carregaro, Adriano Bonfim Corte, Flavio Desessards de La Queiroz Neto, Antonio de |
dc.subject.por.fl_str_mv |
Xilazina Buprenorfina Equinos Sedação Analgesia |
topic |
Xilazina Buprenorfina Equinos Sedação Analgesia Xylazine Buprenorphine Horses Sedation Analgesia CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
dc.subject.eng.fl_str_mv |
Xylazine Buprenorphine Horses Sedation Analgesia |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
description |
The α₂-adrenergic receptor agonists are widely used in equine practice, especially in antalgic therapy, because they promote profound sedation and moderate visceral analgesia. The opioids are used in horses with some restriction due to the excitatory effects in this specie. The objective of this study was to evaluate the sedative effect, hemodynamic, pulmonary and digestory changes due to the neuroleptoanalgesic association of buprenorphine and different doses of xylazine. Six adults horses of both gender, weighting an average of 400 Kg. The animals were control of themselves, being divided into four groups, control group (CG) saline NaCl 0,9% solution administrated IV, and three other groups with buprenorphine 10 μg/kg associated to three different doses of xylazine, 0,25 mg/kg (BX25), 0,50 mg/kg (BX50) and 0,75 mg/kg (BX75) IV. Sedative effects, gastrointestinal motility, FC, f, SAP, MAP, DAP, blood gas tension analysis and core temperature were evaluated 30 min before, immediately before the administration of any treatment for basal values and after 5, 15 and every 15 min until 120 min post-treatment. Gastrointestinal motility was evaluated by the same period and for 12 hours, every 2 hours. Blood samples were collected at 0, 30 and 60 min. Parametric variables were analyzed with ANOVA, followed by Dunnett test for intra group and Tukey test between groups. For the non-parametric variable (intestinal motility) Wilcoxon test was used. Differences was considered significant when P<0.05. Intense sedative effect was observed in the three groups with the neuroleptoanalgesic association lasting 45 min in BX75 with profound ataxia. Intestinal motility decreased with 5 minutes after administration and remained decreased for 8 hours. Hemodynamic parameters started to increased after 30 min and no changes were observed in respiratory frequency and blood gas samples analysis, only HCO3- showed increase. Synergistic effect was observed, maintaining hemodynamic stability, with minimal pulmonary effects. The hypomotility observed must be considered when the association is used in horses with gastrointestinal disorders. |
publishDate |
2008 |
dc.date.issued.fl_str_mv |
2008-08-08 |
dc.date.accessioned.fl_str_mv |
2009-03-09 |
dc.date.available.fl_str_mv |
2009-03-09 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
CRUZ, Fernando Silvério Ferreira da. Physiological changes and sedative effects of the association between buprenorphine and xylazine in horses. 2008. 78 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2008. |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufsm.br/handle/1/8938 |
identifier_str_mv |
CRUZ, Fernando Silvério Ferreira da. Physiological changes and sedative effects of the association between buprenorphine and xylazine in horses. 2008. 78 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2008. |
url |
http://repositorio.ufsm.br/handle/1/8938 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.cnpq.fl_str_mv |
201000000000 |
dc.relation.confidence.fl_str_mv |
400 500 300 500 300 |
dc.relation.authority.fl_str_mv |
a0421801-2f7d-45b2-a7fb-c0b089433af7 e3ab06bd-3d28-4b33-a997-93ba02edaec5 ab8aec2d-f3fe-45a4-8bc3-07256644578f 19e8f84b-7ad7-4606-973b-baf5993524db |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Santa Maria |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Farmacologia |
dc.publisher.initials.fl_str_mv |
UFSM |
dc.publisher.country.fl_str_mv |
BR |
dc.publisher.department.fl_str_mv |
Farmacologia |
publisher.none.fl_str_mv |
Universidade Federal de Santa Maria |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações do UFSM instname:Universidade Federal de Santa Maria (UFSM) instacron:UFSM |
instname_str |
Universidade Federal de Santa Maria (UFSM) |
instacron_str |
UFSM |
institution |
UFSM |
reponame_str |
Biblioteca Digital de Teses e Dissertações do UFSM |
collection |
Biblioteca Digital de Teses e Dissertações do UFSM |
bitstream.url.fl_str_mv |
http://repositorio.ufsm.br/bitstream/1/8938/1/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf http://repositorio.ufsm.br/bitstream/1/8938/2/FERNANDOSILVERIOFERREIRADACRUZ.pdf.txt http://repositorio.ufsm.br/bitstream/1/8938/4/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.txt http://repositorio.ufsm.br/bitstream/1/8938/3/FERNANDOSILVERIOFERREIRADACRUZ.pdf.jpg http://repositorio.ufsm.br/bitstream/1/8938/5/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.jpg |
bitstream.checksum.fl_str_mv |
3e604c1ba91c9deddf24078cec533efa c079ba0edf55cd3487bf2dd8cb441a5b c079ba0edf55cd3487bf2dd8cb441a5b cb148c0b9b3c781472aa1c40a1bb1c68 cb148c0b9b3c781472aa1c40a1bb1c68 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações do UFSM - Universidade Federal de Santa Maria (UFSM) |
repository.mail.fl_str_mv |
atendimento.sib@ufsm.br||tedebc@gmail.com |
_version_ |
1801485312149422080 |